Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Metoprolol

  • Home
  • Metoprolol
Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM
Posted inCardiology news

Aficamten Superior to Metoprolol in Redefining the Structural and Hemodynamic Landscape of Obstructive HCM

Posted by MedXY By MedXY 01/17/2026
The MAPLE-HCM trial reveals that aficamten significantly outperforms metoprolol in reducing LVOT gradients and promoting favorable cardiac remodeling in patients with symptomatic obstructive HCM, signaling a potential shift in first-line therapy.
Read More
Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy
Posted inCardiology Specialties

Aficamten Versus Metoprolol: A New Era in Treating Obstructive Hypertrophic Cardiomyopathy

Posted by MedXY By MedXY 09/10/2025
A multicenter trial demonstrates that aficamten monotherapy outperforms metoprolol in improving exercise capacity and symptoms in obstructive hypertrophic cardiomyopathy (HCM).
Read More
  • Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial
  • Pregnancy in Women With Vascular Malformations Carries High Risks of Postpartum Hemorrhage and Symptom Worsening, While Thromboembolism Clusters in Extensive Lower-Extremity Disease
  • Post-infection Gut-Brain Disorders Affect About 1 in 10 People With DGBI Worldwide, With Distinct Psychological and Regional Patterns
  • PRDM9 Deficiency Identifies a Predominant Molecular Subgroup in Sporadic Hirschsprung Disease and Enables Blood-based Risk Stratification
  • Ultra-Early Remote Ischemic Postconditioning After Thrombectomy Appears Safe but Does Not Improve 90-Day Stroke Recovery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in